- Home
- SKYE vs SKIL Comparison
SKYE vs SKIL Comparison
Compare SKYE & SKIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SKIL
- Stock Information
- Founded
- SKYE 2012
- SKIL 1998
- Country
- SKYE United States
- SKIL United States
- Employees
- SKYE N/A
- SKIL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SKIL Computer Software: Prepackaged Software
- Sector
- SKYE Health Care
- SKIL Technology
- Exchange
- SKYE Nasdaq
- SKIL Nasdaq
- Market Cap
- SKYE 121.8M
- SKIL 141.4M
- IPO Year
- SKYE N/A
- SKIL N/A
- Fundamental
- Price
- SKYE $1.33
- SKIL $17.35
- Analyst Decision
- SKYE Strong Buy
- SKIL
- Analyst Count
- SKYE 5
- SKIL 0
- Target Price
- SKYE $14.75
- SKIL N/A
- AVG Volume (30 Days)
- SKYE 1.8M
- SKIL 61.1K
- Earning Date
- SKYE 11-06-2025
- SKIL 12-09-2025
- Dividend Yield
- SKYE N/A
- SKIL N/A
- EPS Growth
- SKYE N/A
- SKIL N/A
- EPS
- SKYE N/A
- SKIL N/A
- Revenue
- SKYE N/A
- SKIL $524,001,000.00
- Revenue This Year
- SKYE N/A
- SKIL N/A
- Revenue Next Year
- SKYE N/A
- SKIL $0.75
- P/E Ratio
- SKYE N/A
- SKIL N/A
- Revenue Growth
- SKYE N/A
- SKIL N/A
- 52 Week Low
- SKYE $1.14
- SKIL $12.22
- 52 Week High
- SKYE $5.96
- SKIL $34.43
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- SKIL 66.85
- Support Level
- SKYE $1.50
- SKIL $13.60
- Resistance Level
- SKYE $1.76
- SKIL $15.94
- Average True Range (ATR)
- SKYE 0.24
- SKIL 1.27
- MACD
- SKYE -0.15
- SKIL 0.31
- Stochastic Oscillator
- SKYE 0.68
- SKIL 91.37
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experience learner platform that serves learners world-wide. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.